European regulators say they have positively confirmed that the recently recalled MS drug Zinbryta had health risks that outweighed any potential benefits, indicating that causes of severe brain inflammation were…
A new study indicates that Zinbryta side effects were so severe it could have never become a major drug product, raising questions as to why it was approved when there…
The FDA says it will help multiple sclerosis patients transition to other drugs following a Zinbryta recall, and will let it stay on the market until the end of April.
A Zinbryta recall has been announced following 12 cases of brain inflammation, including three deaths, linked to use of the multiple sclerosis drug.
A Zinbryta recall and ban has been recommended in the EU following a dozen reports of serious brain inflammation linked to at least three patient deaths.
